Balaji Amines Limited — Q4 FY25 earnings call

Call held 19 Jun 2025

Management summary

Balaji Amines reported a strong sequential recovery in Q4 FY25, with consolidated revenue, EBITDA, and PAT showing double-digit QoQ growth. However, the full year FY25 performance saw a decline in revenue and profitability compared to FY24, impacted by input costs and pricing pressures. The company is actively pursuing significant capacity expansions and new product commercializations across standalone and subsidiary operations, with several projects slated for commissioning in FY26 and FY27, aiming for future growth despite current market volatility.

Highlights

  • Q4 FY25 Consolidated Revenue from operations: INR361 crores, up 12.5% QoQ.

  • Q4 FY25 Consolidated EBITDA: INR68 crores, up 25.9% QoQ, with an EBITDA margin of 19%.

  • Q4 FY25 Consolidated PAT: INR40 crores, up 29.0% QoQ.

  • FY25 Consolidated Revenue from operations: INR1,430 crores, down 14.5% YoY.

  • FY25 Consolidated EBITDA: INR267 crores (corrected from INR265 crores), down 24.4% YoY, with an EBITDA margin of 19%.

  • FY25 Consolidated PAT: INR159 crores, down 31.5% YoY.

  • Expected minimum volume growth for current FY26: 10% to 12%.

  • Solar power plant (8-megawatt DC) commissioned in April 2025, reducing power costs.

  • Propylene Glycol pharma grade plant expected to be commissioned in Q1 FY26.

Concerns

  • Raw material price volatility due to geopolitical tensions (Iran/Israel war)

  • China overcapacity and dumping impacting product segments (EDA, subsidiary performance)

Key financials

2 periods

Q4 FY25

  • Consolidated Revenue
    ₹361 Cr
    QoQ +12.5%
  • Consolidated EBITDA
    ₹68 Cr
    QoQ +25.9%
  • Consolidated EBITDA Margin
    19%
  • Consolidated PAT
    ₹40 Cr
    QoQ +29%

FY25

  • Consolidated Revenue
    ₹1,430 Cr
    YoY -14.5%
  • Consolidated EBITDA
    ₹267 Cr
    YoY -24.4%
  • Consolidated EBITDA Margin
    19%
  • Consolidated PAT
    ₹159 Cr
    YoY -31.5%

What they filed

Q1 FY27: revenue up 27.4%, net profit up 110.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue347 313 353 358 341 −2%331 +6%395 +12%456 +27%
EBITDA61 46 60 55 60 −2%57 +24%94 +57%116 +111%
Net profit41 31 40 37 37 −10%31 +0%65 +63%78 +111%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Volume
25,872 metric tons Total
  • Specialty Chemicals (Q4 FY25) 9,167 metric tons 35.4%
  • Amines Derivatives (Q4 FY25) 8,389 metric tons 32.4%
  • Amines (Q4 FY25) 8,316 metric tons 32.1%

Guidance & targets

Volume

  • Volume Growth Volume · current financial year · Medium confidence 10-12%
    We are expecting minimum 10% to 12% of the volume growth.

    — D Ram Reddy, Managing Director

Capacity

  • Dimethyl Ether (DME) Commissioning Capacity · FY25-26 · High confidence FY25-26
    Dimethyl ether, it will be commissioned in this financial year '25-'26 only.

    — D Ram Reddy, Managing Director

  • N-Methyl Morpholine (NMM) Commissioning Capacity · FY25-26 · High confidence end of FY25-26
    N-Methylmorpholine also by the end of '25-'26

    — D Ram Reddy, Managing Director

  • Isopropyl Amine Commissioning Capacity · June 2025 · High confidence this week
    Isopropyl amine, actually, plant is ready, will be commissioned. We are waiting to MPCB clearances consent to operate, maybe we get in a week's time. We will be expecting to commercially commissioned by this week.

    — D Ram Reddy, Managing Director

  • Acetonitrile Plant Expansion Commissioning Capacity · FY26-27 · High confidence FY26-27
    Additionally, we are undertaking the capacity expansion for our acetonitrile plant at the Unit III in Chincholi, selling up to 60 metric tons per day, this is expected to be commissioned in the financial year 2026 and '27.

    — D Ram Reddy, Managing Director

  • NBPT Plant Commencement Capacity · FY26 · High confidence next financial year
    This project is expected to commence in the next financial year.

    — D Ram Reddy, Managing Director

  • EDA-based Products Brownfield Expansion Commissioning Capacity · FY26-27 · High confidence FY26-27
    Additionally, a brownfield expansion for EDA-based products at Unit I is on track for commissioning in the financial year '26-'27.

    — D Ram Reddy, Managing Director

Capex

  • Balaji Specialty Chemicals (BSC) Greenfield Project Phase 1 Capex · end of FY25-26 · High confidence INR350-400 crores
    First phase will be about INR350 crores to INR400 crores. And the rest will be in the second phase. In first phase, we will be doing Hydrogen Cyanide, Sodium Cyanide, that is solution and 100%. And so EDTA derivative. These are the products we are going to make in first phase. And the rest other products will come in the second phase.

    — D Ram Reddy, Managing Director

  • Balaji Specialty Chemicals (BSC) Greenfield Project Phase 2 Capex · after FY27 · Medium confidence INR350-400 crores
    Yes, after FY '27. Yes. Once we commission all these plants, then we'll take up those plants.

    — D Ram Reddy, Managing Director

  • Standalone Capex (remaining) Capex · upcoming period · High confidence INR70-80 crores
    There may be about INR70 crores, INR80 crores. And this part of these expenses are pending, all put together, not more than INR200 crores.

    — D Ram Reddy, Managing Director

Capacity Utilization

  • DME Capacity Utilization Capacity Utilization · this year · Medium confidence 50-60%
    The moment we would get the permission, if the acceptance comes from the customer end, we may go minimum 50% to 60% capacity.

    — D Ram Reddy, Managing Director

  • DME Capacity Utilization Capacity Utilization · next year · Medium confidence 70%
    And next year, probably we will do 70% which is 70,000 tons.

    — D Ram Reddy, Managing Director

  • EDA Plant Utilization Capacity Utilization · next year · Medium confidence 80-100%
    So then can we expect 80%, 100% capacity utilization for the other products... Definitely next year.

    — D Ram Reddy, Managing Director

  • N-Butylamine Capacity Utilization Capacity Utilization · next financial year · High confidence >80%
    So, that we are going to take up in the next financial year. So, that time this Butylamines is going to be operational more than 80%.

    — D Ram Reddy, Managing Director

Realization

  • DME Revenue per kg Realization · at commissioning · Low confidence INR70-75
    It's very difficult to say right now, Aditi. The moment we start depends upon the prices, probably it will be INR70 to INR75 per kg, approximately, I'm telling you, depends upon the raw material prices at the time of commissioning.

    — D Ram Reddy, Managing Director

Margin

  • Acetonitrile (ACN) EBITDA Margin Margin · ongoing · Low confidence 19-20%
    It is very difficult in this volatility market paying for a year is very difficult. But as I said earlier, even now I'm also optimum on the EBITDA of around 19% to 20%.

    — D Ram Reddy, Managing Director

Revenue

  • Unit I (existing) Revenue Revenue · next year · Medium confidence INR200-300 crores
    Yes. Next year, both Unit I, the existing unit definitely will do about INR200 crores to INR300 crores minimum in the Unit I.

    — D Ram Reddy, Managing Director

  • Unit II (expansion) Revenue Revenue · next year · Medium confidence INR300-400 crores
    And in Unit II, the expansion unit also may do another INR300 crores to INR400 crores top line.

    — D Ram Reddy, Managing Director

Debt

  • Consolidated Net Debt Debt · by FY27 · Low confidence INR50-100 crores
    After that, if anything required at the end of the finishing these two expansions, we may go INR50 crores, INR100 crores only for the debt by '27. I'm just -- approximately I'm telling you.

    — D Ram Reddy, Managing Director

Other

  • Incentives from State Government Other · 7 years · High confidence over 7 years
    That, we will see whatever the incentive sanctioned will be paid in over a period of 7 years' time.

    — D Ram Reddy, Managing Director

Risks & concerns

  • Raw material price volatility due to geopolitical tensions (Iran/Israel war)

    high

    Methanol prices increased by INR7-8 per kg in the last week, creating uncertainty for future pricing stability.

    Management acknowledged

  • China overcapacity and dumping impacting product segments (EDA, subsidiary performance)

    high

    China dumping has led to reduced capacity utilization for EDA (currently 40-50%) and impacted the subsidiary's performance, with anti-dumping investigations ongoing.

    Management acknowledged

  • Delays in regulatory approvals (PESO) for new product commercialization (DME)

    medium

    The DME plant is ready but awaiting PESO approval for product coding, storage, and road tanker permissions, delaying commercialization.

    Management acknowledged

  • Market volatility impacting margins for certain products (Acetonitrile)

    medium

    Management noted the difficulty of predicting margins in a volatile market for products like Acetonitrile, aiming for 19-20% EBITDA.

    Management acknowledged

Areas of evasion (1)

  • Specific technology partner for Sodium Cyanide

Q&A highlights

2 direct
Project Timelines and Commercialization Direct
Dimethyl ether, it will be commissioned in this financial year '25-'26 only. N-Methylmorpholine also by the end of '25-'26, Isopropyl amine, actually, plant is ready, will be commissioned. We are waiting to MPCB clearances consent to operate, maybe we get in a week's time. We will be expecting to commercially commissioned by this week.

Provides specific, updated timelines for several key new projects, crucial for future revenue visibility and capex utilization.

Asked by Ahmed Madha

Consolidated Net Debt Outlook by FY27 Partial
After that, if anything required at the end of the finishing these two expansions, we may go INR50 crores, INR100 crores only for the debt by '27. I'm just -- approximately I'm telling you.

Addresses concerns about the balance sheet impact of significant capex, providing an approximate and relatively low debt level post-expansion.

Asked by Anil Shah

Revenue Decline Despite Capex & Capacity Utilization Direct
That's what I am telling you my dear, the plant is yet to start. The money spent, but we are waiting for the permission. The moment we get the permission, we'll start these revenues.

Explains the apparent contradiction of significant capex spend not yet translating into revenue growth, attributing it to commissioning delays and pending regulatory approvals.

Asked by Anil Shah

3 min read 7 chapters

Detailed narrative

Q4 FY25 Performance Overview

Balaji Amines reported a strong sequential improvement in Q4 FY25. Consolidated revenue from operations increased to INR361 crores, up 12.5% from INR321 crores in Q3 FY25. EBITDA grew by 25.9% QoQ to INR68 crores, with the EBITDA margin expanding to 19% from 17%. Consolidated PAT also saw a significant QoQ increase of 29.0% to INR40 crores. Total volumes for the quarter reached 25,871 metric tons, a 7.3% QoQ increase, driven by stable demand from the pharmaceutical sector.

Full Year FY25 Financials and Challenges

For the full financial year 2025, consolidated revenue from operations stood at INR1,430 crores, a 14.5% decline from INR1,671 crores in FY24. Consolidated EBITDA was INR267 crores (corrected from INR265 crores), down 24.4% YoY, resulting in a 19% EBITDA margin compared to 21% in FY24. PAT for FY25 decreased by 31.5% YoY to INR159 crores. Management attributed the full-year challenges to input cost pressures, pricing volatility, and global uncertainties.

Strategic Capacity Expansion & New Projects (Standalone)

The company is actively expanding its capacities and product portfolio. The 8-megawatt DC solar power plant was commissioned in April 2025, contributing to cost reduction and ESG goals. The Propylene Glycol pharma grade plant is expected to be commissioned in Q1 FY26. The Dimethyl Ether (DME) and N-Methyl Morpholine (NMM) plants are planned for commissioning by the end of FY26. Additionally, an acetonitrile plant expansion to 60 metric tons per day is expected by FY27, and a new NBPT plant is slated for commencement in the next financial year.

Subsidiary (Balaji Specialty Chemicals) Expansion

Balaji Specialty Chemicals Limited (BSC), the subsidiary, is executing a greenfield project worth approximately INR750 crores. Phase 1, focusing on Hydrogen Cyanide, Sodium Cyanide, and EDTA derivatives, is valued at INR350-400 crores and is expected to be commissioned by the end of FY26. Phase 2, also INR350-400 crores, will follow after FY27. A brownfield expansion for EDA-based products at Unit I is also on track for commissioning in FY26-27, aiming to enhance the product portfolio.

DME Commercialization & Market Outlook

The DME plant, with a total capacity of 100,000 tons, is ready for commissioning, pending PESO regulatory approvals. Management anticipates 50-60% capacity utilization in the current year, potentially increasing to 70% next year, with an estimated revenue of INR70-75 per kg. DME is positioned as an alternative for LPG, with BIS allowing 20% blending, and also targets the aerosol market and industrial heating applications, offering significant market potential upon regulatory clearance.

Impact of External Factors & Raw Material Volatility

The company faces challenges from external factors, including volatile agrochemical demand and rising raw material prices. Methanol prices increased by INR7-8 per kg recently due to geopolitical tensions between Iran and Israel, creating uncertainty for profitability. China's dumping practices continue to impact the EDA segment, leading to current utilization of 40-50% and ongoing anti-dumping investigations, which have also affected the subsidiary's overall performance.

Capacity Utilization & Product Mix Strategy

Current N-Butylamine capacity utilization stands at 30-35%, with management expecting it to exceed 80% next financial year, aiming to capture 90-95% of India's import demand. The company is also upgrading its Dimethyl Carbonate (DMC) plants for Electronic DMC, commissioned in May 2025. Furthermore, Balaji Amines is pursuing a pharmaceutical grade license for Propylene Glycol, which would enable the plant to operate at over 60-70% capacity even without full demand from battery chemicals, diversifying revenue streams.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls